EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
7:00am - 8:00am 60 mins
Info
Continental Breakfast - Hilton Union Square

Hilton Union Square, Grand Ballroom

7:00am - 6:00pm 660 mins
Info
Registration Open - Hilton Union Square

Hilton Union Square, Plaza A, Lobby Level

8:00am - 8:55am 55 mins
Info
Investing in next gen immunotherapies: Moving the checkpoint inhibitors to the next level - Hilton Union Square
  • Moderator Jeffrey Bockman - Executive VP, Oncology Practice Head, Defined Health, a Cello Health Business
  • Panelist Asthika Goonewardene - Senior Biotechnology Analyst, Bloomberg Intelligence
  • Panelist Bibhash Mukhopadhyay - Principal, New Enterprise Associates
  • Panelist Robert Ross - Chief Medical Officer, Surface Oncology Inc
  • Panelist Thomas J. Schuetz - Co-Founder and CEO, Compass Therapeutics

Hilton Union Square, Yosemite C

While the frenzy around funding immuno-oncology agents has started to settle down from its peak in 2015–2016, the question remains open as to which if any of these many “first generation” programs for solid tumors looking to enhance the activity of checkpoint inhibitors and/or attempting to render colder tumors hotter will actually provide the next big shift in clinical management. Data to date has been disappointing to mixed at best. When looking to the future of immunotherapy, one wonders if there will be for the foreseeable future only more incremental advances. But where are the next big paradigm shifts going to be, where is the next great target that will supersize foundational checkpoint therapy? This panel will probe these issues especially as they relate to creating value not only for investors and potential partners but most critically for patients.

8:00am - 8:55am 55 mins
Info
NASH MOAs: A highly competitive playing field - Hilton Union Square
  • Moderator Yasmeen Rahimi - Managing Director, Senior Research Analyst, Roth
  • Panelist Carol Gallagher - Partner, NEA
  • Panelist Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk
  • Panelist Brian Lian - President and CEO, Viking Therapeutics
  • Panelist Rohan Palekar - CEO, 89Bio

Hilton Union Square, Yosemite A

With many new drugs and molecular targets in development and no FDA-approved therapeutics to treat NASH, the competitive environment is heating up. Although there is increased interest in NASH, the complexity as a multi-factorial disease and the long time frame for drug development is not without challenges. What are the key pros and cons of the multiple key mechanisms of action and will there be an approval in 2019?

8:00am - 6:00pm 600 mins
Info
One-to-one meetings - Hilton Union Square

Hilton Union Square, Grand Ballroom

8:00am - 8:25am 25 mins
Info
Introduction and industry update - Parc 55
  • Speaker Janet Lambert - CEO, Alliance for Regenerative Medicine

Parc 55 San Francisco, Cyril Magnin Ballroom 

8:25am - 9:05am 40 mins
Info
Cell therapy commercialization in oncology - Parc 55
  • Panelist Joanna Beck - Executive VP, Global Pharmaceutical Development and Operations, Celgene Corporation
  • Panelist Maria Fardis - President and CEO, Iovance Biotherapeutics
  • Panelist Steven Kelly - President and CEO, CARISMA Therapeutics
  • Panelist Christopher Vann - Chief Operating Officer, Autolus Therapeutics

Parc 55 San Francisco, Cyril Magnin Ballroom

8:30am - 12:00pm 210 mins
Info
Company Presentations - Hilton Union Square

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

9:05am - 9:50am 45 mins
Info
The outlook for gene therapy in 2019 - Parc 55
  • Panelist Matthew Patterson - Chairman and CEO, Audentes Therapeutics; Chairman, Alliance for Regenerative Medicine
  • Panelist Arthur Tzianabos - President and CEO, Homology Medicines
  • Panelist Jeffrey Walsh - Chief Financial and Strategy Officer, bluebird bio

Parc 55 San Francisco, Cyril Magnin Ballroom

12:00pm - 1:45pm 105 mins
Info
Lunch Plenary: The booming biotech ecosystem: The playing field has evolved, and the bases are loaded. How long will the streak continue? - Hilton Union Square
  • Moderator Barbara Ryan - Founder, Barbara Ryan Advisors
  • Panelist Michelle Keefe - President, Commercial Solutions, Syneos Health
  • Panelist William Newell - CEO, Sutro Biopharma, Inc.
  • Panelist Art Pappas - Managing Partner, Pappas Capital
  • Panelist James H. Sabry - Global Head, Pharma Partnering, Roche
  • Panelist Camille Samuels - Partner, Venrock

Hilton Union Square, Imperial Ballroom

The biotech industry is booming, with growing confidence in the sector, more financing options than ever before, and valuations driving ever higher. In this new, frenetic normal, how can companies prepare for potential turbulence? Success hinges on meaningful engagement with an increasing number of stakeholders, a much earlier and clearer definition of an asset’s value and leveraging of new capabilities to shorten the timeline to approval—all while remaining flexible and nimble. This panel will explore the changing global market forces and what it’s going to take for biotech to succeed in the face of new demands.  

1:45pm - 5:30pm 225 mins
Info
Company Presentations - Hilton Union Square

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

4:00pm - 5:00pm 60 mins
Info
An H&Q reunion: A retrospective look at the biotech sector with former analysts - Hilton Union Square
  • Moderator Dennis J. Purcell - Founder and Senior Advisor, Aisling Capital
  • Panelist Kristin Carey - Managing Director, Cain Brothers
  • Panelist Meg Malloy, Music Therapy
  • Panelist Rich van den Broek - Partner, HSMR Advisors
  • Panelist Tim Wilson - CEO, IGEM Therapeutics Ltd
  • Panelist Alex Zisson - Managing Director, H.I.G. Capital

Hilton Union Square, Imperial Ballroom

Showing of Streams